Halozyme Therapeutics, Inc.
NASDAQHalozyme Therapeutics enters the week in an unusual position: the put/call ratio has surged to a near-annual high even as the Street's analyst consensus remains firmly bullish, and short sellers are quietly adding to a position that already represents more than 12% of the free float. The sharpest signal this week is in options. Monday's put/call ratio hit 2.32 — well above its…
HALO put-call ratio explodes to 2.11, highest level in 52 weeks—signaling extreme bullish options positioning as stock rallies 33% in one month.
Snapshot as of 23 Sept 2026
Halozyme Therapeutics enters the week in an unusual position: the put/call ratio has surged to a near-annual high even as the Street's analyst consensus remains firmly bullish, and short sellers are quietly adding to a…
HALO enters September with a striking divergence: options traders are leaning heavily bullish while short sellers have quietly rebuilt positions after a dramatic August earnings pop. The options market is sending an…
Halozyme Therapeutics is in an unusual spot three days after its 23% earnings pop — the stock has stalled at $102.62 while shorts, far from covering, have barely moved. Short interest is marginally lower than it was…
Halozyme Therapeutics delivered a jolt to the market this week — a 23% single-day move on August 7 following strong Q2 results, leaving a meaningful short position scrambling and analysts rushing to lift targets…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for HALO — free to start on ORTEX.
Sign up for free →Open HALO on ORTEX